AMYLYX PHARMACEUTICALS INC (AMLX) Stock Income Statement
NASDAQ:AMLX - Nasdaq - US03237H1014 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | -607.00K | 87.37M | 380.79M | 22.23M | 285.00K | |||
| Cost Of Goods | 8.23M | 32.13M | 25.44M | 2.99M | N/A | |||
| Gross Profit | -8.83M | 55.24M | 355.35M | 19.24M | N/A | |||
| Operating Expenses | 162.52M | 218.41M | 316.54M | 220.58M | 82.97M | |||
| Research and Development | 89.59M | 104.08M | 128.19M | 93.45M | 44.04M | |||
| Selling, General, and Administrative Expenses | 72.26M | 114.33M | 188.36M | 127.13M | 38.93M | |||
| Operating Income | -171.35M | -163.18M | 38.80M | -201.34M | -82.69M | |||
| Interest Income/Expense | 11.71M | 13.81M | 16.16M | 4.29M | 36.00K | |||
| Other Income/Expense | -802.00K | -1.21M | -660.00K | -551.00K | -5.28M | |||
| Non Recurring Items | N/A | -151.55M | N/A | N/A | N/A | |||
| Income Before Taxes | -219.49M | -302.14M | 54.30M | -197.60M | -87.93M | |||
| Income Tax | N/A | -393.00K | 5.03M | 774.00K | N/A | |||
| Net Income | -218.86M | -301.74M | 49.27M | -198.38M | -87.93M | |||
| EBITDA | -170.60M | -162.27M | 39.89M | -200.85M | -82.64M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.11 | -4.43 | 0.70 | -3.39 | -1.56 | |||
| Non GAAP EPS | -2.77 | -2.47 | 0.70 | -3.43 | N/A | |||
| Statistics | ||||||||
| Gross Profit Margin | 1455.35% | 63.22% | 93.32% | 86.54% | N/A | |||
| Profit Margin | 36055.52% | -345.36% | 12.94% | -892.38% | -30852.98% | |||
| Operating Profit Margin | 28229.00% | -186.76% | 10.19% | -905.72% | -29013.33% | |||
All data in USD